Insulet (NASDAQ:PODD) Shares Down 5.2% – Should You Sell?

Insulet Corporation (NASDAQ:PODD)’s stock price traded down 5.2% on Monday . The stock traded as low as $158.01 and last traded at $155.8650. 61,738 shares changed hands during trading, a decline of 95% from the average daily volume of 1,243,904 shares. The stock had previously closed at $164.48.

Analysts Set New Price Targets

PODD has been the topic of a number of analyst reports. Robert W. Baird cut their price objective on shares of Insulet from $360.00 to $248.00 in a report on Thursday, May 7th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $280.00 target price on shares of Insulet in a report on Wednesday, May 27th. Bank of America dropped their price target on shares of Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Weiss Ratings cut shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, June 24th. Finally, Piper Sandler reduced their price objective on shares of Insulet from $360.00 to $210.00 in a research report on Wednesday, May 6th. Twenty-two analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $237.83.

Insulet Price Performance

The stock has a market cap of $11.02 billion, a PE ratio of 36.82, a P/E/G ratio of 1.15 and a beta of 1.11. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The firm’s 50 day moving average price is $155.23 and its two-hundred day moving average price is $215.38.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same period in the prior year, the company posted $1.02 EPS. Insulet’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts expect that Insulet Corporation will post 6.46 earnings per share for the current year.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.36% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Glenmede Investment Management LP increased its position in shares of Insulet by 1.6% during the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 35 shares during the period. Curi Capital LLC boosted its position in shares of Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after acquiring an additional 36 shares during the period. WINTON GROUP Ltd boosted its position in shares of Insulet by 0.9% in the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock valued at $1,261,000 after acquiring an additional 37 shares during the period. Great Lakes Advisors LLC grew its stake in Insulet by 1.5% during the fourth quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock valued at $791,000 after acquiring an additional 40 shares in the last quarter. Finally, Camarda Financial Advisors LLC grew its stake in Insulet by 0.5% during the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after acquiring an additional 40 shares in the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.